



10565278 - GAU- 1634

PTO/SB/088 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/565,278
Filing Date	July 20, 2004
First Named Inventor	SCHMUTZ, Sheila Marie
Art Unit	1655
Examiner Name	TBA
Attorney Docket Number	046423-0006US

Sheet 1 of 2

## NON PATENT LITERATURE DOCUMENTS

Examiner initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/KS/		Arnarger V., M. Nguyen, A.S. Van Laere, M. Braunschweig, C. Nezer, M. Georges, and L. Andersson. 2002. Comparative sequence analysis of the WS-IGF2- H19 gene cluster in pigs. Mamm Genome 13(7):388-98.	
		<del>Genodermatosis in Associations of Swine (Genet. 2003)</del>	
/KS/		De Chiara, T.M., Efstratiadis, A. and Robertson, E.J. 1990. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345: 78-82	
		De Chiara, T.M., Robertson, E.J. and Efstratiadis, A. 1991. Parental imprinting of the mouse insulin-like growth factor two gene. Cell 64: 849-859.	
		Giannoukakis, N., Deal, C. Paquette, J. Goodyer, C.G. and Polychronakos, C. 1993. Paternal genomic imprinting of the human IGF2 gene. Nat. Genetics. 4: 98-101.	
		Goodall, J. J. 2002. Undergraduate thesis title: Characterization of the Insulin-like growth factor II gene in cattle.	
		Goodall, J.J. and Schmutz, S.M. 2003. Linkage Mapping of IGF2 on Cattle Chromosome 29. Anim. Genet. 34 (4): 313.	
		Holtzman P., Van der Lee F.M., Ikejiri K., Yamamoto M., and J.S. Sussenbach. 1990. Identification and initial characterization of a fourth leader exon and promoter of the human IGF2 gene. Biochim. Biophys. Acta 1087:341-3.	
		Jeon, J.T., Carlborg, O. Tornsten, A. Giuffra, E. Amarger, V. Chardon, P. Andersson Euklund, L. Andersson, K. Hannesson, I. Lundstrom, K. and Andersson, L. 1999. A paternally expressed QTL affecting skeletal and cardiac muscle mass in pigs maps to the IGF2 locus. Nat. Genetics. 21: 157-158.	
↓		Kalscheuer, V.M., Mariman, E.C. Schepens, M.T. Rehder, H. and Ropers, H.H. 1993. The insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans. Nat. Genetics. 5: 74-78.	

Examiner Signature /Katherine Salmon/

Date Considered 11/07/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
This document contains information that is not to be released outside the U.S. Patent and Trademark Office unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/565,278
Filing Date	July 20, 2004
First Named Inventor	SCHMUTZ, Sheila Marie
Art Unit	1655
Examiner Name	TBA
Attorney Docket Number	046423-0006US

Sheet 2 of 2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/KS/		McLaren, R.J. and Montgomery, G.W. 1999. Genomic imprinting of the insulin-like growth factors 2 gene in sheep. Mamm. Genome 10: 588-591.	
		Nezer, C., Moreau, L., Brouwers, B., Coppieters, W., Detilleux, J., Hanset, R., Karim, L., Kvasz, A., Leroy, P., and Georges, M. 1999. An imprinted QTL with major effect on muscle mass and fat deposition maps to the IGF2 locus in pigs. Nat. Genetics. 21: 155-156.	
		Ohlsson, R., Nystrom, A., Pfeiffer-Ohlsson, S., Tohonen, V., Hedberg, F., Schofield, P., Elam, F. and Ekstrom, T.J. 1993. IGF2 is paternally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat. Genetics. 4: 94-97.	
		Ohlsen S.M., Lugenbeel K.A., and E.A. Wong. 1994. Characterization of the Linked Insulin and IGF2 genes. DNA and Cell Bio. 13:377-88.	
		De Pagter-Holthuisen P., Jansen M., Van Schaik F.M.A., Van der Kammen R., Oostervijk C., Van de Brande J. L. and J.S. Sussenbach. 1987. The human IGF2 gene contains two development-specific promoters. FEBS Lett. 214:259-64.	
		De Pagter-Holthuisen P., Jansen M., Van der Kammen R.A., Van Schaik F.M.A., and J.S. Sussenbach. 1988. Differential expression of the human IGF2 gene. Characterization of the IGF2 mRNAs and an mRNA encoding a putative IGF2 associated protein. Biochim.Biophys. Acta 950:282-95.	
		Rohwein, P. and Hall, L.J. 1990. Evolution of insulin-like growth factor 2: Characterization of the mouse IGF2 gene and identification of two pseudo-exons. DNA. Cell Biol. 9: 725-735.	
		Sasaki, H., Jones, P.A., Chaillet, J.R., Ferguson-Smith, A.C., Barton, S.C., Reik, W. and Surani, M.A. 1992. Parental imprinting: potentially active chromatin of the repressed maternal allele of the mouse insulin-like growth factor II gene. Genes and Development. 6: 1848-1856.	
		Schmutz S.M., Moker, J.S., Gallager, Jr. D.S., Kappers, S.M. and Womack, J.E. 1996. In situ hybridization mapping of LDHA and IGF2 to cattle chromosome 29. Mamm. Genome. 7:473.	
↓		Goodall J.J. and S.M. Schmutz. 2007. IGF2 gene characterization and association with rib eye area in beef cattle. Anim.Genet. 38:154-161.	

Examiner  
Signature

/Katherine Salmon/

Date  
Considered

11/07/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation (number optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.